Tratamiento farmacológico de la fase depresiva del trastorno bipolar (depresión bipolar). Segunda parte
Year: 2004
Type: article
Abstract: Bipolar disorder is a major public health problem, affecting approximately 1.3 ± 0.2 % of the Mexican population. In addition
to the subjects personal suffering, bipolar disorders places
substantial burdens on health care services, families, caregivers
and employers. In the World Health Organization’s Global Burden
of Disease study, bipolar disorder ranked sixth among all medical
disorders in years of life lost to death or disability.
Bipolar depression, or the depressive phase of bipolar disorder,
represents a difficult- to- treat and disabling form of depression.
However, in regard to its impact, an insufficient number of studies
have explored its treatment. Studies indicate that patients with
bipolar disorder spend more time in treatment and take longer to
recover from the depressive phase that from the manic phase.
Patients with bipolar disorder, experience depressive symptoms
more than 3 times more longer than they experience manic
symptoms. The median time to recovery from the depressive phase
is 9 weeks but from the manic phase is 5 weeks; 22 % of the
patients in the depressive phase and only 7 % in the manic phase
remained ill for at least 1 year. The median time to full remission
is 16.8 weeks for a manic episode but 40 weeks for a depressive
episode. In addition to being longer and more persistent, the
depressive phase of bipolar disorder is associated with higher
rates of morbidity and mortality. The relative risk of suicide
among patients with bipolar depression is 34.9 times greater than
that among patients with pure mania. Despite the clear clinical
implications of these findings, treatment of bipolar depression
remains an understudied area, as clinicians and researchers have
historically focused on treatment of mania. Although a wide
range of mood-stabilizing medications is available, treatment
options for bipolar depression remain more limited. The 2002
treatment guidelines from the American Psychiatric Association
recommended either lithium or lamotrigine as first-line treatment.
Although reviews of clinical trials have concluded that there is
evidence of lithium’s acute efficacy for bipolar depression,
anticonvulsants such as lamotrigine and valproate have also been
used to treat bipolar depression. However, lamotrigine requires a
slow upward titration to avoid the risk of rash. Other treatments
include the adjunctive use of antidepressants with a mood
stabilizer. However, antidepressants, may cause problems due to
their potential to induce mania or hypomania or to accelerate
cycling.
This paper reviews controlled studies of bipolar depression,
outlines criteria for choosing treatment, and provides options for
treatment of refractory bipolar depression. The author conducted
a comprehensive review of English-language literature describing
peer- reviewed and quality class A controlled trials in order to
identify agents used for bipolar disorder. Controlled studies to
examine the efficacy of treatments for acute bipolar depression
were located through electronic searches of several databases and
by manual cross search of references and proceedings of
international meetings. Lithium: There are no double-blind,
parallel-design, placebo-controlled studies that have examined
the efficacy of lithium monotherapy in comparison with placebo
in acute bipolar depression. However, the efficacy of lithium was
examined in three placebo-controlled cross-over studies and all
of them showed lithium’s superiority over placebo. Available
data supports the efficacy of lithium in acute bipolar depression.
Valproate: A recent placebo-controlled, parallel-design study,
examined the efficacy of valproate monotherapy. Intent-to-treat
analysis indicated that 43 % of the subjects randomized to
valproate and 27 % randomized to placebo met criteria for
recovery (p= .04), but mean change from baseline in HAM-D
scores were similar at the end-point to the placebo group. The
negative findings in this study could be due to a smaller sample
size, so this suggests the efficacy of valproate in acute bipolar
depression but this needs to be verified in further larger- scale
double- blind trials. Carbamazepine: Carbamazepine has some
efficacy, but further studies are needed before firm conclusions
can be drown. Lamotrigine: In the largest double-blind, placebocontrolled, parallel study of bipolar depression to date, the
lamotrigine 200 mg/day group showed a significantly greater
improvement compared with the placebo group on the
Montgomery-Asberg Depression Rating Scale (MADRS) and the
Clinical Global Impression-Improvement (CGI-I) scale. In another
10-weekdouble-blind trial in bipolar I and bipolar II depressed
patients, above all, no significant differences were noted using
last observation carried forward (LOCF). However, a subgroup
analysis revealed significant differences favoring lamotrigine in
bipolar I but not in bipolar II depressed patients. The efficacy of
lamotrigine in preventing depressive episodes in bipolar I disorder
was examined in two recent double-blind placebo-controlled
studies. In one of the studies, patients with bipolar I disorder
who were currently or recently in a manic or hypomanic phase
were treated with lamotrigine monotherapy or add on therapy to
other psychotropic medications. Survival analysis showed that
lamotrigine was significantly superior to placebo in time, for any
mood episode or depressive episode. In the other study, bipolar I
depressed patients were treated in an open-label design with
lamotrigine monotherapy or add on therapy and those meeting
the stabilization criteria were randomized to double-blind
treatment with one of three fixed doses of lamotrigine
monotherapy, lithium monotherapy or placebo for 18 months.
Results using survival analysis indicated that lamotrigine was
significantly superior to placebo in delaying time of intervention
for any mood episode or a depressive episode. The results of these
two double-blind trials clearly indicate that lamotrigine is effective
in delaying depressive relapses and recurrences in bipolar I patients.
There is no evidence to indicate that lamotrigine induces rapid
cycling in bipolar patients. Gabapentine: The efficacy of gabapentine
monotherapy in comparison with lamotrigine or placebo was
examined over a 6-week period in patients with refractory mood
disorders. The results of this study indicate that lamotrigine is
effective in 45 % of the patients, and gabapentine is no more
effective than placebo in treating depressive symptoms. Topiramate:
No double-blind studies have been reported on the efficacy of
topiramate monotherapy in bipolar depression. Antidepressants: In
double-blind active comparator studies, response rates to
imipramina were comparable with the response rates to fluoxetine
through significantly lower when compared with tranylcypromine.
Atypical antipsychotics: Olanzapine is the only atypical antipsychotic
that has been tested for its efficacy in a double-blind, placebocontrolled trial in bipolar depression. Response rates were 48.2 %
in the olanzapine group, 64.8 % in the olanzapine plus fluoxetine
group, and 36.1 % in the placebo group. The results of this study
indicate olanzapine’s monotherapy efficacy in treating acute bipolar
depression.
Conclusions: The literature reviewed above indicates that lithium
is the only efficient medication in acute bipolar depression and in
preventing depressive episodes, and that it has no propensity to
induce a manic switch or rapid cycling; also, it should be the firstline treatment for bipolar depression. Lamotrigine is also efficient
in acute bipolar depression, and in preventing depressive episodes,
but its efficacy in preventing manic episodes has not been proven.
The magnitude of the antidepressant effect of olanzapine appears
to be somewhat smaller than other established antidepressant
medications as well as lamotrigine. The other anticonvulsants,
antidepressants, or atypical antipsychotics cannot be recommended
as first-line treatments for bipolar depression.
Source: Salud Mental
Author: Enrique Chávez-León
Institution: Universidad Anáhuac
Language: Spanish
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: bipolar depression, bipolar disorder, pharmacotherapy, mood stabilizers, lithium, lamotrigine, valproic acid, antidepressants, adjunctive antidepressant therapy, antidepressant-induced mania, antidepressant-induced hypomania, suicide risk, treatment guidelines, antiepileptic drugs, disease burden
Open Access status: diamond
OpenAlex ID: W52555125
